Genvoya
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
- Strength
- 150 mg/1, 150 mg/1, 200 mg/1, 10 mg/1
- Form
- Tablet
- Class
- Cytochrome P450 3A Inhibitor; Hepatitis…
Gilead Sciences, Inc.
Not stocked by us — reference only
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
Listed by Gilead Sciences, Inc.
This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.
| Dosage form | Tablet, Film Coated |
|---|---|
| Route | Oral |
| Drug class | Cytochrome P450 3A Inhibitor; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor |
| Approval route | NDA — original brand approval |
| NDC code | 61958-1201 |
| FDA application | NDA203100 |
| RxNorm concept | 1306292 |
| Package sizes listed | 1 |
| Marketed since | August 2012 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Gilead Sciences, Inc.
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.